Evidence map›Paper›PMID 41882476›Full record

ArticleJournal of neurovirology2026

A cross-cohort comparison of the prevalence and clinical significance of Alzheimer's disease biomarkers in people with versus without HIV.

Lillian Ham, Olivia Villers, Judith D Lobo, Tyler R Bell, Debralee Cookson, Douglas Galasko, Scott L Letendre, Mark W Bondi, David J Moore, Erin E Sundermann

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lillian HamSan Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-6163-9700
Olivia VillersUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Judith D LoboHIV Neurobehavioral Research Program, University of California San Diego, 220 Dickinson Street, Suite B, San Diego, CA, 92103, USA.
Tyler R BellDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Debralee CooksonHIV Neurobehavioral Research Program, University of California San Diego, 220 Dickinson Street, Suite B, San Diego, CA, 92103, USA.
Douglas GalaskoDepartment of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Scott L LetendreHIV Neurobehavioral Research Program, University of California San Diego, 220 Dickinson Street, Suite B, San Diego, CA, 92103, USA.
Mark W BondiDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
David J MooreHIV Neurobehavioral Research Program, University of California San Diego, 220 Dickinson Street, Suite B, San Diego, CA, 92103, USA.
Erin E SundermannHIV Neurobehavioral Research Program, University of California San Diego, 220 Dickinson Street, Suite B, San Diego, CA, 92103, USA. esundermann@health.ucsd.edu.

Funding

HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Comparative Study of Molecular Signatures in HIV-Related Neuropathogenesis and Alzheimer's DiseaseR01AG061066 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GALASKO, DOUGLAS R · 2018 to 2022
$3.8M
NIAID NIH HHS T32 AI007384NIA NIH HHS R01 AG061066
6 · The paper itself

Abstract

With over half of people with HIV (PWH) in the U.S. entering older adulthood, identifying markers to distinguish Alzheimer’s disease (AD) and its precursor, amnestic mild cognitive impairment (aMCI), from other forms of neurocognitive impairment among PWH is urgent. We examined how HIV and aMCI status relate to AD CSF biomarkers in adult PWH and people without HIV (PWoH) characterized for aMCI. We included 80 PWH from the National NeuroHIV Tissue Consortium and 80 PWoH from the Wisconsin Registry for Alzheimer’s Prevention. Binary logistic regressions of AD-related CSF biomarker positivity (Aβ42, Aβ42/Aβ40, t-tau, p-tau181, Aβ42/t-tau) were conducted with HIV serostatus, aMCI status, HIV x aMCI interaction, and demographic covariates. Among PWH, we examined how HIV-disease characteristics relate to AD biomarker positivity. No HIV x aMCI interactions were detected. Regardless of aMCI status, having HIV was associated with higher odds of CSF Aβ42 (OR = 7.97) and Aβ42/Aβ40 (OR = 6.06) positivity, suggesting increased cerebral Aβ plaque burden. Regardless of HIV serostatus, having aMCI was associated with higher odds of CSF p-tau181 positivity (OR = 3.64). Neither HIV nor aMCI status related to Aβ42/t-tau positivity. No HIV-disease characteristics related to AD biomarker positivity. Higher CSF Aβ positivity in PWH versus PWoH, regardless of aMCI status, suggests that HIV disease promotes amyloidosis; however, whether positive CSF biomarkers in PWH raises risk for future cognitive impairment and AD remains to be explored longitudinally. Like PWoH, elevated CSF p-tau181 among PWH may indicate increased risk for AD-related memory impairment.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCognitive DysfunctionHIV Infectionstau ProteinsAgedBiomarkersFemaleHumansMaleMiddle AgedPeptide FragmentsPrevalenceAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAgingAmyloidCognitionDementiaNeurocognitive disordersTauopathies

Identifiers

PMID41882476
PMCPMC13018001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.